NANOBIOTIX announced the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 for its previously announced (July 10, 2023) global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (?Janssen?), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3. With the expiration of the HSR waiting period, the transaction has become effective, and as such, Nanobiotix is eligible to receive payment of the $30 million upfront cash licensing fee.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.03 EUR | -2.99% | -21.71% | -24.25% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.25% | 262M | |
+49.21% | 56.95B | |
+39.98% | 40.26B | |
-6.86% | 39.32B | |
-4.42% | 28.37B | |
+12.00% | 26.45B | |
-18.27% | 19.41B | |
+29.57% | 12.54B | |
+25.41% | 12.21B | |
-0.35% | 12.15B |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix
- NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3